DelveInsight’s, “ER+/ HER2-VE Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in ER+/ HER2 -ve Breast Cancer Research. Learn more about our innovative pipeline today! @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook
Key Takeaways from the ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report
- DelveInsight’s ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment.
- The leading ER+/ HER2 -ve Breast Cancer Companies such as BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
- Promising ER+/ HER2 -ve Breast Cancer Therapies such as G1T48, Palbociclib, and others.
Stay informed about the cutting-edge advancements in ER+/ HER2 -ve Breast Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ ER+/ HER2 -ve Breast Cancer Clinical Trials Assessment
ER+/ HER2 -ve Breast Cancer Emerging Drugs Profile
- AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
- BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
Learn more about ER+/ HER2 -ve Breast Cancer Drugs opportunities in our groundbreaking In ER+/ HER2 -ve Breast Cancer Research and development projects @ ER+/ HER2 -ve Breast Cancer Unmet Needs
ER+/ HER2 -ve Breast Cancer Therapeutics Assessment
There are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. The ER+/ HER2 -ve Breast Cancer companies which have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
DelveInsight’s ER+/ HER2 -ve Breast Cancer pipeline report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Discover the latest advancements in ER+/ HER2 -ve Breast Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives
ER+/ HER2 -ve Breast Cancer Companies
BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
For a detailed overview of our latest research findings and future plans, read the full details of ER+/ HER2 -ve Breast Cancer Pipeline on our website @ ER+/ HER2 -ve Breast Cancer Drugs and Companies
Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report
- Coverage- Global
- ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- ER+/ HER2 -ve Breast Cancer Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
- ER+/ HER2 -ve Breast Cancer Therapies- G1T48, Palbociclib, and others.
Table of Content
- Introduction
- Executive Summary
- ER+/ HER2-VE Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- AZD9833: Astrazeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BGB-290: BeiGene
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- OP-1250: Olema Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- ER+/ HER2-VE Breast Cancer Key Companies
- ER+/ HER2-VE Breast Cancer Key Products
- ER+/ HER2-VE Breast Cancer- Unmet Needs
- ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
- ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
- ER+/ HER2-VE Breast Cancer Analyst Views
- ER+/ HER2-VE Breast Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/